AR101840A1 - Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene - Google Patents
Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contieneInfo
- Publication number
- AR101840A1 AR101840A1 ARP150102901A ARP150102901A AR101840A1 AR 101840 A1 AR101840 A1 AR 101840A1 AR P150102901 A ARP150102901 A AR P150102901A AR P150102901 A ARP150102901 A AR P150102901A AR 101840 A1 AR101840 A1 AR 101840A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- human papillomavirus
- seq
- gene
- gene encoding
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 18
- 241000701806 Human papillomavirus Species 0.000 abstract 11
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 101710121996 Hexon protein p72 Proteins 0.000 abstract 3
- 101710125418 Major capsid protein Proteins 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008364 bulk solution Substances 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000010195 expression analysis Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un gen aislado que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4 y SEQ ID Nº 5. Reivindicación 2: Un vector que comprende el gen que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5, y su combinación. Reivindicación 6: Una célula huésped caracterizada porque comprende el vector tal como se reivindica en la reivindicación 2. Reivindicación 11: Una vacuna contra el virus del papiloma humano, caracterizada porque comprende al menos un gen que codifica la proteína del cápside entre las reivindicadas en la reivindicación 1, que puede generar una respuesta inmunitaria contra el antígeno del HPV. Reivindicación 16: Un método para preparar la vacuna contra el virus del papiloma humano tal como se reivindica en la reivindicación 11, caracterizado porque comprende los siguientes pasos: a) síntesis del gen que codifica la proteína de la cápside mayor del virus del papiloma humano; b) construcción del vector de expresión para el gen que codifica la proteína de la cápside mayor del virus del papiloma humano; c) selección del clon con un número alto de copias del gen transformado de dicha proteína del virus del papiloma humano; d) análisis de expresión del gen transformado de dicha proteína del virus del papiloma humano; e) purificación de la proteína codificada por el gen de dicha proteína del virus del papiloma humano; f) preparación de solución a granel de VLPs de dicha proteína del virus del papiloma humano; g) caracterización de dicha proteína en la célula huésped; h) preparación de la vacuna que contiene dicha proteína del virus del papiloma humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2905MU2014 | 2014-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101840A1 true AR101840A1 (es) | 2017-01-18 |
Family
ID=54843870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102901A AR101840A1 (es) | 2014-09-11 | 2015-09-11 | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3191505A2 (es) |
| JP (1) | JP2017528137A (es) |
| CN (1) | CN107002085A (es) |
| AR (1) | AR101840A1 (es) |
| AU (1) | AU2015313756A1 (es) |
| BR (1) | BR112017004181A2 (es) |
| CA (1) | CA2958222A1 (es) |
| EA (1) | EA201790365A1 (es) |
| MA (1) | MA40624A (es) |
| WO (1) | WO2016038625A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104845985B (zh) * | 2014-02-18 | 2020-02-07 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒蛋白表达 |
| US20180311340A1 (en) | 2015-10-19 | 2018-11-01 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
| CN109750049B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒52亚型蛋白表达 |
| JP2021502822A (ja) * | 2017-11-14 | 2021-02-04 | フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． | ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス |
| US11389519B2 (en) * | 2018-06-11 | 2022-07-19 | Inventprise, Llc | Virus-like particle conjugates |
| GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| BR102020006846A2 (pt) * | 2020-04-03 | 2021-12-07 | Imunoscan Engenharia Molecular Ltda | Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0863982B1 (en) * | 1995-11-15 | 2004-01-21 | Merck & Co., Inc. | Synthetic hpv11 virus-like particles |
| DK0973546T3 (da) * | 1997-04-08 | 2004-06-28 | Merck & Co Inc | Stabiliserede formuleringer med human papillomavirus |
| EP1015561B1 (en) * | 1997-09-05 | 2006-07-19 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps) |
| MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| WO2005123762A2 (en) * | 2004-06-18 | 2005-12-29 | Indian Immunologicals Ltd | Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16 |
| CN101487009B (zh) * | 2008-01-15 | 2012-11-21 | 上海泽润生物科技有限公司 | 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法 |
| WO2009076824A1 (zh) * | 2007-11-23 | 2009-06-25 | Shanghai Zerun Biotechnology Co., Ltd. | 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途 |
| HRP20141063T1 (hr) * | 2008-07-31 | 2015-01-02 | Glaxosmithkline Biologicals S.A. | Cjepivo protiv hpv |
| CN102215861B (zh) * | 2009-06-19 | 2014-10-08 | 艾金株式会社 | 宫颈癌疫苗 |
| CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
| CN103648528A (zh) * | 2011-05-13 | 2014-03-19 | 弗利亚生物技术公司 | 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途 |
| JP6050811B2 (ja) * | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| CN103667319B (zh) * | 2012-09-10 | 2017-09-26 | 同济大学 | 抗人乳头瘤病毒的三价疫苗及其制法和用途 |
-
2015
- 2015-09-11 JP JP2017513424A patent/JP2017528137A/ja active Pending
- 2015-09-11 BR BR112017004181A patent/BR112017004181A2/pt not_active Application Discontinuation
- 2015-09-11 AR ARP150102901A patent/AR101840A1/es unknown
- 2015-09-11 EP EP15808033.3A patent/EP3191505A2/en not_active Withdrawn
- 2015-09-11 MA MA040624A patent/MA40624A/fr unknown
- 2015-09-11 CN CN201580049136.4A patent/CN107002085A/zh active Pending
- 2015-09-11 AU AU2015313756A patent/AU2015313756A1/en not_active Abandoned
- 2015-09-11 WO PCT/IN2015/000355 patent/WO2016038625A2/en not_active Ceased
- 2015-09-11 CA CA2958222A patent/CA2958222A1/en not_active Abandoned
- 2015-09-11 EA EA201790365A patent/EA201790365A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107002085A (zh) | 2017-08-01 |
| WO2016038625A3 (en) | 2016-04-28 |
| EP3191505A2 (en) | 2017-07-19 |
| MA40624A (fr) | 2016-03-17 |
| JP2017528137A (ja) | 2017-09-28 |
| AU2015313756A1 (en) | 2017-03-09 |
| BR112017004181A2 (pt) | 2017-12-05 |
| EA201790365A1 (ru) | 2017-07-31 |
| CA2958222A1 (en) | 2016-03-17 |
| WO2016038625A2 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101840A1 (es) | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| MY187462A (en) | Modified virus-like particles of cmv | |
| WO2012106377A3 (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| MX361893B (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
| MX379069B (es) | Vacunas terapeuticas contra el vph16. | |
| PH12020500526A1 (en) | Paramyxoviridae expression system | |
| EP4450516A3 (en) | A vaccine for use in the prophylaxis and/or treatment of a disease | |
| MX380631B (es) | Vectores de adenovirus canino | |
| NZ759538A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| PH12019500557A1 (en) | New ehv insertion site orf70 | |
| CY1118704T1 (el) | Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου | |
| AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| MX391049B (es) | Nuevos promotores | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| EA202092164A1 (ru) | Новый ehv с инактивированным ul18 и/или ul8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |